The EmPCAD Study

The purpose the EmPCAD study is to develop inexpensive, noninvasive cognitive screening tools which help to detect the earliest signs of Alzheimer’s disease pathology in people before they have symptoms of the disease. This study will evaluate several memory tests in cognitively normal older adults to determine if they are sensitive to evidence of Alzheimer’s disease brain changes based on cerebrospinal fluid (CSF) analysis.

Individuals 60-89 years of age who are cognitively normal may be eligible, and no study partner is required.

The EmPCAD study seeks participants already enrolled in the Penn Memory Center longitudinal cohort of the NACC study or participants who have completed equivalent testing.